All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec007}
============

Routine screening for atrial fibrillation (AF) is currently not endorsed by the UK National Screening Committee \[[@pmed.1003197.ref001]\]. The growing prevalence of AF \[[@pmed.1003197.ref002],[@pmed.1003197.ref003]\] and its associated life-changing health implications \[[@pmed.1003197.ref004],[@pmed.1003197.ref005]\], combined with the impact of AF on national health resources \[[@pmed.1003197.ref006]\] that can occur as a result of the disease not being detected early, have led to a growing medical consensus, backed by public health policy, to improve the early detection and treatment of AF \[[@pmed.1003197.ref007]--[@pmed.1003197.ref009]\].

The prevalence and severity of AF increases with age \[[@pmed.1003197.ref010]\], and the older-aged population are most at risk of experiencing an AF-related stroke and/or heart failure \[[@pmed.1003197.ref004],[@pmed.1003197.ref005]\]. Furthermore, the risk of the disease has been shown to be exacerbated when associated with other co- or multimorbidities, such as hypertension and heart failure \[[@pmed.1003197.ref005],[@pmed.1003197.ref011]--[@pmed.1003197.ref014]\]. For persons aged 55 y or older, the lifetime risk of developing AF increases from one in five to one in three in the presence of one or more morbidities \[[@pmed.1003197.ref011]\]. The proportion of over-65s experiencing two or more chronic conditions is 54%, increasing to 69% for those over the age of 85 \[[@pmed.1003197.ref015]\]. Thus, the older, ageing population remains key to any future national screening plans, as highlighted by the European Society of Cardiology (ESC) guidelines \[[@pmed.1003197.ref008]\]. When, where, and how this population is targeted remains a key consideration to any future screening initiatives, in order to maximise socioeconomic outcomes.

Primary care is considered to be central to improving the early detection of AF, as this is where the majority of the populations' health is routinely managed. In England, general practitioner (GP) surgeries provide over 300 million patient consultations a year \[[@pmed.1003197.ref016]\], making this location ideal for health screening \[[@pmed.1003197.ref017]--[@pmed.1003197.ref021]\]. The chronic shortage of doctors and nurses in the UK \[[@pmed.1003197.ref022]\], and elsewhere, impacts heavily on patient access to primary care \[[@pmed.1003197.ref023]\], despite efforts to retain and increase GP numbers \[[@pmed.1003197.ref024]\]. To address this issue, NHS England have pledged to fund an additional 20,000 healthcare professionals (HCPs) by 2023/2024 to support GPs \[[@pmed.1003197.ref025]\], with initial funding targeted to social prescribers and pharmacists. This builds on previous NHS investment into the 'Clinical Pharmacists in General Practice' pilot scheme, which, since 2015, has recruited over 1,000 full-time clinical pharmacists \[[@pmed.1003197.ref026]\]. As such, healthcare interventions such as AF screening are likely to be delivered by another HCP, other than a GP. Clinical pharmacists are well placed to apply their in-depth knowledge of medicines, toxicology, pharmacokinetics, and therapeutics to deliver patient-centred care that promotes health, well-being, and disease prevention, in all patient-care settings \[[@pmed.1003197.ref027],[@pmed.1003197.ref028]\]. The development of newer and better screening methods for AF are also being shown to improve the detection of AF and are helping to overcome some of the limitations and barriers experienced using older, more conventional methods \[[@pmed.1003197.ref029],[@pmed.1003197.ref030]\].

In this 'Pharmacists Detecting Atrial Fibrillation' (PDAF) study, we aimed to determine the feasibility of general practice--based clinical pharmacists screening the over-65s for AF, using digital technology and a single-time-point screening strategy combined with another annual healthcare intervention, the influenza vaccination. We evaluated the use of a single-lead electrocardiogram (~SL~ECG) device compared with pulse palpation alone, as the latter is a current recommendation for AF detection \[[@pmed.1003197.ref031]\], and the economic impact of both methods particularly in relation to false-discovery rates (FDRs). Finally, we sought feedback from the participants about the service that was provided. A preliminary account of some of these data has been reported previously \[[@pmed.1003197.ref032]\].

Methods {#sec008}
=======

This study is reported as per the Standards for Reporting Diagnostic accuracy studies (STARD) checklist ([S1 STARD Checklist](#pmed.1003197.s001){ref-type="supplementary-material"}).

Study design {#sec009}
------------

A single-time-point screening strategy was used to detect AF in patients aged 65 y or over attending the annual influenza vaccination at their GP practice, using clinical pharmacists to conduct the screening. Screening was conducted over two influenza vaccination seasons, from 28 October 2017 to 22 February 2018 and then from 2 October to 14 December 2018. The study protocol design was described in a previous publication \[[@pmed.1003197.ref033]\]. In brief, five clinical pharmacists were recruited from Kent Community NHS Foundation Trust, another pharmacist was already embedded in a participating practice, and another was provided by the Medway School of Pharmacy, University of Greenwich and Kent. All pharmacists received training before and during the study to implement the screening protocol. Four GP practices across the NHS Canterbury and Coastal Clinical Commissioning Group participated in the study. Patients aged 65 or over attending an influenza clinic at a participating practice were eligible to have the rate and rhythm of their heart assessed, using pulse palpation and an ~SL~ECG device (AliveCor Kardia Mobile Device \[KMD\]). Exclusions from screening included anyone with a pacemaker, those with a severe coexisting medical condition (e.g., cancer with \<1 month (mo) of life expectancy), or those who were not able to provide informed consent at time of screening because of a lack of mental capacity. Patients with preexisting AF were not excluded, as it was assumed that most participants with AF would self-exclude, whereas those that did not would act as positive test controls. Pharmacists were unaware of preexisting AF diagnoses in participants prior to screening. Participants could be screened at the clinic or could opt for a prebooked appointment. Screening was advertised via posters, leaflets, text messages, staff, clinical pharmacists, or a member of the study team. Participants were recruited using a consecutive sampling approach, meaning that any participants attending influenza vaccination clinics at participating practices during the studied time periods and fulfilling the study inclusion criteria (see above) were invited to participate. All data with an exception of enhanced participant demographics were collected prospectively.

Screening procedure {#sec010}
-------------------

All eligible participants provided signed informed consent before entering the study. Consenting participants were assigned a deidentifying patient ID code, which was then used on all study documentation and recorded ECGs. Participants were asked to complete a basic demographics form (e.g., age, sex, ethnicity, height, weight, current smoking and drinking habits) prior to screening. Screening then followed the process outlined in [Fig 1](#pmed.1003197.g001){ref-type="fig"}. The radial pulse of the participant was measured for 60 seconds (s), and this was then followed by an ~SL~ECG, recorded for 30 s. Only one ECG was recorded, unless the ECG was of poor quality, then a second was recorded. The data of the last ECG recorded for each participant were used for subsequent analysis. The ECG was assessed and interpreted by the clinical pharmacist. Their assessment of the ECG was explained to the participant and noted, along with the quality of the ECG recording. The clinical pharmacists were not blinded from knowing the provisional diagnosis of the KMD algorithm. All ECGs were emailed to the study cardiologist via the NHS.net email system for overreading. The clinical pharmacist provided the participant with a provisional diagnosis letter that was either 'normal', 'possible AF', 'unclassified' (not sinus rhythm \[SR\] or AF), or 'unreadable' and advised of the next steps. All ECGs were uploaded to participants' electronic medical record and copies of the consent form and provisional diagnosis letter retained in the study file. The cardiologist's interpretation of the ECG and recommendations for intervention were returned within 72 hours (h). The cardiologist was not blinded from knowing the provisional diagnoses by KMD algorithm or pharmacists and provided pharmacists with regular feedback once each provisional diagnosis was confirmed or rejected. All patient interventions, including confirmatory 12-lead ECGs (~12L~ECGs), were organised by the GP practice in accordance with their normal practice procedures. All participants given either an AF or unclassified/unreadable diagnosis and a recommendation for further intervention by the cardiologist were followed-up by the study team to ensure participants had been offered appropriate treatment from their GP practice. The study team also collated enhanced demographics (e.g., medical history) from all patients with either an AF or unclassified/unreadable diagnosis and a random selection (*n* = 100) of participants who had normal SR at time of screening, for comparison (7/100 participants were excluded from this selection, as their medical records showed that they had either had experienced/were experiencing known AF/paroxysmal AF \[PAF\]). This sample of participants was selected using the random-cases function of SPSS (v25) in the presence of two researchers.

![Pharmacists Detecting Atrial Fibrillation study intervention flowchart.\
AF, atrial fibrillation; GP, general practitioner; HR, heart rate; PIL, participant information leaflet.](pmed.1003197.g001){#pmed.1003197.g001}

Participant experience questionnaire {#sec011}
------------------------------------

At the end of the screening appointment, all participants were asked to complete a short, anonymous, patient experience questionnaire consisting of 13 closed and four open questions ([S1 Appendix](#pmed.1003197.s003){ref-type="supplementary-material"}) and were offered the opportunity to take part in future focus groups (reported elsewhere). Completed questionnaires were handed over to the receptionist or posted back to the research team using prepaid envelopes.

Quantitative data analysis {#sec012}
--------------------------

Apart from the subgroup analysis pertaining to enhanced demographic data of selected participants with suspected 'normal' diagnoses, all data analyses were conducted as prespecified in the study protocol \[[@pmed.1003197.ref033]\]. Continuous variables were reported as a median (interquartile range). Categorical variables, including responses to closed questions of the participant experience questionnaire, were expressed as numbers and percentages (%). The demographics of individuals with and without AF were compared using a Mann-Whitney U test for continuous variables and a Pearson chi-squared or Fisher exact test for categorical variables. Any missing data points were omitted from final analysis, without data imputation. For all statistical comparisons, *p*-values of \<0.05 were considered significant.

The level of interrater agreement between pulse palpation, pharmacist, device, and cardiologist interpretation of the ~SL~ECG was calculated using Cohen's kappa statistic. Diagnostic accuracy measures, including the sensitivity, specificity, percentage agreement with the cardiologist (positive predictive value \[PPV\]), and the FDR, for each index test were derived from 2 × 2 contingency tables using cardiologist's interpretation of ~SL~ECG as a reference test. The sensitivity and specificity of the test were defined as its ability to correctly identify those participants with AF (true positives/true positives and false negatives) and without AF (true negatives/true negatives and false positives), respectively \[[@pmed.1003197.ref034]\]. The overall diagnostic accuracy (correct classification rate) combined these two measures as an assessment of the test's ability to detect both the proportions of true positives and true negatives (true positive and true negatives/total number of participants) \[[@pmed.1003197.ref035]\]. The PPV and FDR were defined as probabilities that the test will identify those with positive diagnoses either correctly (PPV = number of participants who both tested positive and were true positives/total number who tested positive) or incorrectly (FDR = number of participants who both tested positive and were true negatives/total number who tested positive), respectively \[[@pmed.1003197.ref034],[@pmed.1003197.ref036]\].

The diagnostic accuracy of pulse palpation, clinical pharmacist's interpretation, and the device's algorithm (index tests) was compared with the cardiologist's interpretation (reference standard) using a Cochran Q test followed by post hoc McNemar chi-squared tests and a Bonferroni correction for multiple comparisons. Diagnostic accuracy measures were expressed as a mean (95% confidence intervals \[CIs\]).

Prevalence of new AF diagnoses were determined from the number of confirmed AF-positive ~12L~ECGs divided by the total number screened with accompanying 95% CI. False-positive results of each index test were expressed as the number of incorrect AF diagnoses compared with the cardiologist's interpretation, divided by the total number screened (95% CI). All analyses were performed using IBM Statistical Package for Social Sciences (SPSS V.25).

Responses to open-ended questions of participant experience questionnaires were imported into NVivo (V.12) and analysed using content analysis \[[@pmed.1003197.ref037]\], a systematic approach commonly applied to the analysis of verbatim questionnaire data \[[@pmed.1003197.ref038]\]. This included coding the words and frequencies extracted from the questionnaires to identify the frequency of their occurrence and to group them into key themes. The themes were considered alongside responses to closed questions.

Patient and public involvement {#sec013}
------------------------------

The AF screening protocol and all patient-related information and documents were presented to and scrutinised by the Medway School of Pharmacy, Public Involvement in Pharmacy Studies (PIPS) group prior to submission for ethics approval. Members were also involved in mock training sessions with the clinical pharmacists. The PIPS group comprises interested members of the public. No members of the PIPS group participated in the screening.

The results of the study have been disseminated to participants via various forums including GP practice newsletters, press and media releases (BBC South East, KMTV, and BBC Radio Kent), and social media.

Ethics {#sec014}
------

The study was approved by the London-Riverside Research Ethics committee (17/LO/1650) and NHS Health Research Authority. IRAS Project ID is 232663. The study was conducted in accordance with the Medical Research Council's framework for complex interventions \[[@pmed.1003197.ref039]\] and the recommendation for physicians involved in research on human participants adopted by the 18th World Medical Assembly, Helsinki 1964, and later revisions.

Results {#sec015}
=======

Participants {#sec016}
------------

A total of 604 participants across four GP practices in Kent underwent a heart rhythm check with a clinical pharmacist. Median age (interquartile range) of the participants was 73 (69--78) y and 42.7% of participants were male. The majority of participants (96.9%) reported themselves to be White British and had a median body mass index (BMI) of 26.1 (23.5--29.3), [Table 1](#pmed.1003197.t001){ref-type="table"}. Nearly 85% of participants only had one ~SL~ECG recording (512/604), although two or more ECGs were performed in 15.2% of participants (92/604) in which the first recording was of poor quality.

10.1371/journal.pmed.1003197.t001

###### A summary of participant demographic characteristics (*n* = 604).

![](pmed.1003197.t001){#pmed.1003197.t001g}

  Characteristics                                        *N* = 604
  ------------------------------------------------------ ----------------------------------
  **Age, years**                                         73 (69--78)
  **Male**                                               258 (42.7%)
  **White British**                                      585 (96.9%)
  **White Irish**                                        3 (0.5%)
  **White American**                                     2 (0.3%)
  **White Dutch**                                        2 (0.3%)
  **White other[\*](#t001fn002){ref-type="table-fn"}**   7 (1.2%)
  **Other[\*\*](#t001fn003){ref-type="table-fn"}**       5 (0.8%)
  **Current alcohol drinker**                            380 (62.9%)
  **Alcohol, units/week**                                6 (2--14) (*n* = 372)
  **Current smoker**                                     54 (8.9%)
  **Height, cm**                                         167.0 (160.0--174.0) (*n* = 596)
  **Weight, kg**                                         73.0 (64.0--83.0) (*n* = 588)
  **BMI, kg/m**^**2**^                                   26.1 (23.5--29.3) (*n* = 585)
  **Heart rate device, bpm**                             72 (65--81)

Continuous variables are expressed as a median (interquartile range). Categorical variables are expressed as a number of participants (% total of the group).

\*White European, Flemish, Italian, Scottish, and South African (*n* = 1 each), and White nonspecified or other (*n* = 2).

\*\*Kazakh, American, Australian, Hungarian, and Norwegian (*n* = 1 each).

Abbreviations: BMI, body mass index; bpm, beats per minute (heart rate).

Screening for AF: Measurement comparison {#sec017}
----------------------------------------

### Cardiologist {#sec018}

The cardiologist was able to interpret 99% of the ~SL~ECGs recorded, with only 1% (6/604) of the ~SL~ECG recorded deemed uninterpretable. From 598/604 ~SL~ECGs, the cardiologist diagnosed 503 (83.3%) as normal SR, 26 (4.3%) as possible AF, and 69 (11.4%) as either having unidentifiable or absent P waves or having some other non-AF cardiac abnormality, such as bundle branch block (BBB) and atrioventricular block (AVB) ([Fig 2](#pmed.1003197.g002){ref-type="fig"}).

![Screening for AF, measurement comparison.\
A breakdown of diagnoses derived from pulse palpation, KMD algorithm, and pharmacist interpretation of the ~SL~ECG compared with the cardiologist's interpretation of the ~SL~ECG. All data are expressed as the number of cases in each diagnostic category (% diagnostic agreement with cardiologist diagnoses). \**p* = 0.001 for differences derived from 2 × 2 contingency tables for AF-positive and AF-negative diagnoses between KMD and pulse palpation and between pharmacist interpretation and pulse palpation. AF, atrial fibrillation; KMD, Kardia Mobile Device; ~SL~ECG, single-lead ECG.](pmed.1003197.g002){#pmed.1003197.g002}

### ~SL~ECG interpretation by the KMD algorithm {#sec019}

The KMD algorithm reported 484 (80%) cases as normal SR, 39 (6.5%) cases of possible AF, 75 (12.4%) as unclassified, and six (1.0%) of the ECGs as unreadable. Diagnostic agreement of the algorithm's interpretation of the ~SL~ECG compared with the cardiologist's interpretation is illustrated in [Fig 2](#pmed.1003197.g002){ref-type="fig"}, whereas sensitivity, specificity, and accuracy of diagnosing AF from an ~SL~ECG are shown in [Table 2](#pmed.1003197.t002){ref-type="table"}. The KMD had a false-positive rate of 2.6% and an FDR of 38.5%.

10.1371/journal.pmed.1003197.t002

###### A summary of diagnostic accuracy.

Interpretation of ~SL~ECG by the KMD algorithm, pharmacist interpretation, and pulse palpation when compared with the cardiologist interpretation (expressed as a mean (95% CI)).
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  Index Test                  Sensitivity    Specificity    Accuracy (Correct Classification Rate)   False-Discovery Rate   Cohen's Kappa
  --------------------------- -------------- -------------- ---------------------------------------- ---------------------- ---------------
  KMD algorithm               92.3           97.4           97.2                                     38.5                   0.72
  (74.9--99.1)                (95.8--98.5)   (95.5--98.4)   (23.4--55.4)                             (0.60--0.85)           
  Pharmacist interpretation   88.5           97.2           96.9                                     41.0                   0.69
  (69.9--97.6)                (95.5--98.4)   (95.1--98.1)   (25.6--57.9)                             (0.56--0.82)           
  Pulse palpation             76.9           92.2           91.6                                     69.2                   0.40
  (56.4--91.0)                (89.7--94.3)   (89.1--93.7)   (56.6--80.1)                             (0.27--0.53)           

Abbreviations: CI, confidence interval; KMD, Kardia Mobile Device; ~SL~ECG, single-lead ECG.

### ~SL~ECG interpretation by the clinical pharmacists {#sec020}

From the ~SL~ECG, clinical pharmacists were asked to record their own interpretation of the ~SL~ECG (normal SR, possible AF, unclassified, or unreadable). The clinical pharmacists reported 487 (80.6%) cases as normal SR, 39 (6.5%) cases of possible AF (35 of these matched with the KMD algorithm), 71 (11.8%) unclassified, and seven (1.2%) of the ECGs as unreadable. Diagnostic agreement of the clinical pharmacist's interpretation of the ~SL~ECG compared with the cardiologist's interpretation is illustrated in [Fig 2](#pmed.1003197.g002){ref-type="fig"}, whereas sensitivity, specificity, and accuracy of diagnosing AF from an ~SL~ECG by the clinical pharmacists are shown in [Table 2](#pmed.1003197.t002){ref-type="table"}. The clinical pharmacists' interpretation of the ~SL~ECG had a false-positive rate of 2.8% and an FDR of 41.0%. The quality of the ~SL~ECG recorded for 604 participants was deemed as either excellent (60%), acceptable (33%), poor (5%), or unreadable (2%) by the pharmacists.

### Pulse palpation by the clinical pharmacist {#sec021}

Heart rate and rhythm interpretation of the pulse was obtained by the pharmacist for 603 participants, with pulse interpretation data missing for one case, in which pulse could not be palpated. Average heart rate was determined by the pharmacist to be 70 beats per minute (bpm) (62--78), compared with 72 bpm (65--81), *n* = 604, obtained using the KMD.

Using pulse palpation alone, pharmacists reported 526 (87.1%) cases as normal SR, 65 (10.8%) cases of possible AF, 12 (2.0%) as unclassified, and one (0.2%) as unreadable (i.e., impalpable). Diagnostic agreement of pulse palpation with the cardiologist's interpretation of the ~SL~ECG is illustrated in [Fig 2](#pmed.1003197.g002){ref-type="fig"}, whereas sensitivity, specificity, and accuracy of diagnosing AF using pulse palpation are shown in [Table 2](#pmed.1003197.t002){ref-type="table"}. For pulse interpretation, the false-positive rate and FDRs were high (7.8% and 69.2%, respectively). False-positive AF diagnoses occurred as a consequence of multiple atrial or ventricular ectopic beats (*n* = 23), mild sinus tachycardia (*n* = 2), or bradycardia (*n* = 1), where indicated by the cardiologist's interpretation of the ~SL~ECG.

AF prevalence {#sec022}
-------------

The total prevalence of 'known' and 'new' AF ascertained by the cardiologist's interpretation of ~SL~ECG recordings was 4.3% (26/604). Of these 26 participants, 18/26 (3.0%) had a known medical history of AF, were in AF when screened, and no further action was taken. A total of eight (1.3%) possible-AF participants were referred for a ~12L~ECG. Three (0.5%) of these referred participants remained in AF at time of the ~12L~ECG. In total, 4/604 (0.7%) participants were diagnosed with 'new' AF as a result of screening after a ~12L~ECG confirmation (three with initially suspected 'possible AF' and one with an 'unclassified' diagnosis). Interestingly, of the 18 'known' AF patients, all of whom were receiving oral anticoagulant (OAC) treatment, only seven reported at the time of screening that they experienced AF and were receiving anticoagulation therapy, and three participants were unsure about their diagnosis or treatment, warranting a confirmation in their medical records. All 26 'known' and 'actionable' AF participants were eligible for OACs in accordance with ESC guidelines \[[@pmed.1003197.ref008]\]. Of the 26 participants eligible for OAC therapy, 20 (76.9%) were on OAC therapy at the end of the study (18 with 'known' and two with 'new AF'). An additional participant with a provisional 'unclassified' diagnosis who was diagnosed with 'new' AF following a ~12L~ECG was anticoagulated accordingly.

Demographics of 'new' and 'known' AF participants {#sec023}
-------------------------------------------------

Participants with AF were more likely to be male; were significantly older (*p* \< 0.0001); had a significantly higher BMI (*p* = 0.01); and a CHA~2~DS~2~-VASc score ≥ 3 (*p* = 0.002), compared with a random sample (*n* = 93) of participants that were deemed normal SR, at time of screening ([Table 3](#pmed.1003197.t003){ref-type="table"}). Extended demographics of participants identified with AF showed that they were significantly more likely to experience hypertension, renal disease, diabetes mellitus, and heart failure ([Table 3](#pmed.1003197.t003){ref-type="table"}). Average number of comorbidities per participant from within the AF cohort was 2.0 (1.0--3.0) (*n* = 26), compared with 1.0 (0.0--2.0) for the non-AF cohort (*n* = 93).

10.1371/journal.pmed.1003197.t003

###### A comparison of demographic characteristics between a random sample of participants with normal diagnoses (*n* = 93) versus those with cardiologist-confirmed AF diagnoses (*n* = 26).
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                                              Random Sample With Normal Diagnoses (*n =* 93)   Participants With Cardiologist-Confirmed AF Diagnoses (*n =* 26)   *p*-Value (Two-Sided)
  ------------------------------------------- ------------------------------------------------ ------------------------------------------------------------------ -----------------------
  **Age, years**                              72 (69--76)                                      82 (73--85)                                                        \<0.0001
  **Male**                                    36 (38.7)                                        15 (57.7)                                                          0.116
  **Current alcohol drinker**                 72 (77.4)                                        16 (61.5)                                                          0.103
  **Alcohol, units/week**                     5.5 (2--14) (*n* = 70)                           10.0 (2--14) (*n =* 16)                                            0.482
  **Current smoker**                          6 (6.5)                                          3 (11.5)                                                           0.408
  **Height, cm**                              170.0 (162.5--175.0) (*n* = 91)                  167.5 (162.5--177.5)                                               0.634
  **Weight, kg**                              73.0 (65.1--81.9) (*n* = 90)                     78.3 (69.7--97.0)                                                  0.055
  **BMI, kg/m**^**2**^                        25.7 (23.1--28.0) (*n* = 89)                     28.5 (24.2--33.5)                                                  0.010
  **CHA**~**2**~**DS**~**2**~**VASc score**   3.0 (2.0--3.0) (*n* = 93)                        3.0 (3.0--4.3)                                                     0.002
  **Hypertension**                            38 (40.9)                                        18 (69.2)                                                          0.010
  **Renal disease**                           16 (17.2)                                        11 (42.3)                                                          0.007
  **Diabetes mellitus**                       12 (12.9)                                        8 (30.8)                                                           0.041
  **Thyroid disease**                         8 (8.6)                                          4 (15.4)                                                           0.293
  **Transient ischaemic attack**              3 (3.2)                                          3 (11.5)                                                           0.117
  **Ischaemic heart disease**                 7 (7.5)                                          3 (11.5)                                                           0.454
  **Heart failure**                           0 (0.0)                                          2 (7.7)                                                            0.046
  **Intracranial bleed**                      1 (1.1)                                          1 (3.8)                                                            0.391
  **Peripheral vascular disease**             4 (4.3)                                          0 (0.0)                                                            0.575
  **COPD**                                    8 (8.6)                                          2 (8.0)                                                            1.000

Continuous variables are expressed as a median (interquartile range). Categorical variables are expressed as a number of participants (% total of the group).

Abbreviations: AF, atrial fibrillation; BMI, body mass index; CHA~2~DS~2~-VASc, Congestive heart failure, Hypertension, Age ≥ 75, Diabetes, previous Stroke, Vascular disease, Age 65--74 years, Sex category; COPD, chronic obstructive pulmonary disease

Cost-effectiveness evaluation {#sec024}
-----------------------------

The cost-effectiveness of PDAF intervention (see [S1 Supporting Information](#pmed.1003197.s002){ref-type="supplementary-material"}) was estimated with a Markov simulation model built using the cost-utility template by Edlin and colleagues \[[@pmed.1003197.ref040]\], the National Institute for Health and Care Excellence (NICE) costing report for AF \[[@pmed.1003197.ref041]\], and methodology adapted from two previous AF screening studies \[[@pmed.1003197.ref042],[@pmed.1003197.ref043]\]. Cost-effectiveness was evaluated for the KMD and compared with pulse palpation alone or no screening intervention. The intervention was considered to be cost-effective if the estimated incremental cost-effectiveness ratio was under the willingness-to-pay threshold of £20,000/quality-adjusted life year (QALY) proposed by NICE \[[@pmed.1003197.ref044]\]. At base case assumptions (see [S1 Supporting Information](#pmed.1003197.s002){ref-type="supplementary-material"}), the AF screening strategy was found to be cost-effective in 71.8% and 64.3% of estimates (100,000 simulations run in each case) for KMD and pulse palpation, respectively, compared with no screening intervention. The incremental net benefit compared with no screening strategy was £1,903/patient using the KMD and £946/patient using pulse palpation. If applied to all patients over 65 y old across England and Wales, with 50% uptake of screening and AF newly detected as a result of this screening, this would represent incremental net benefits of around £120 million using the KMD and £50 million using pulse palpation alone.

Follow-up data and outcomes {#sec025}
---------------------------

Following the initial screening and the cardiologist's interpretation of the ~SL~ECG, 87/604 (14.4%) participants with either possible AF or some other cardiac abnormality were referred for a ~12L~ECG or heart rate check ([Fig 3](#pmed.1003197.g003){ref-type="fig"}). The median time between screening and ~12L~ECG was 16.0 (11.0--24.0) days (d). One participant declined a ~12L~ECG and GP review, and four participants did not respond to an invitation. Of the remaining participants, 28 (4.6%) had normal SR (some identified by GP before ~12L~ECG was done); 22 (3.6%) had a previously diagnosed condition and required no further intervention; four had newly diagnosed AF (0.7%), of whom three (0.5%) were initiated on oral anticoagulation; and 28 (4.6%) had a newly diagnosed non-AF cardiovascular condition. Further details concerning the 28 non-AF conditions identified from the ~SL~ECG device and reclassifying of patients following ~12L~ECG are shown in [Fig 3](#pmed.1003197.g003){ref-type="fig"}. None of the participants with a new first-degree AVB (1.3%, 8/604) were referred for pacemaker implantation.

![Flowchart of follow-up actions and outcomes.\
~12L~ECG, 12-lead ECG; AEB, atrial ectopic beats; AF, atrial fibrillation; AVB, first-degree atrioventricular block; BBB, bundle branch block; GP, general practitioner; HR, heart rate; LVH, left ventricular hypertrophy; ~SL~ECG, single-lead electrocardiogram; SR, sinus rhythm; VEB, ventricular ectopic beats.](pmed.1003197.g003){#pmed.1003197.g003}

Participant experience questionnaire {#sec026}
------------------------------------

Of the 604 participants screened, 422 (70%) completed a feedback questionnaire. All responding participants rated the overall screening experience as either 'very good' or 'good', and 99% agreed that they would be happy to take part in annual repeat AF screening. Less than half of all respondents (47%) were aware of AF as a condition before they were screened. However, 96% of respondents felt that routine AF screening was either 'very important' or 'important' post screening. In response to open-ended questions, when asked 'Was there anything you particularly liked about the service?', there were 272 recorded comments. Of these, 75 participants praised the 'professional' (14) yet 'relaxed', 'friendly', and 'at ease' nature of the pharmacist-led screening (61), and 24 stated that the service improved their access to healthcare by offering an opportunity to obtain a more rapid provisional diagnosis and reassurance about their health status. Ninety-four participants were particularly pleased with the 'informative' consultation during which they learnt about AF and any information was clearly presented in lay terms they could understand and feel comfortable about, and seven stated that they were particularly impressed with the digital technology that was used. A number of participants (32) particularly liked being able to contribute to clinical research that had a 'preventative medicine' focus. When participants were asked 'Was there anything you particularly disliked about the service?', there were only six comments, with length of time of the appointment noted for two.

Discussion {#sec027}
==========

Principal findings {#sec028}
------------------

This study produced a number of key findings. Firstly, it showed that clinical pharmacists, assisted by the KMD, were able to detect 24 out of 26 possible AF diagnoses, when compared with the overreading cardiologist. Secondly, participants with confirmed AF had a higher incidence of co- or multimorbidities, including hypertension, renal disease, diabetes, and heart failure. All 'known' and previously 'unknown' AF participants were at risk of stroke and eligible for OACs. Thirdly, screening for AF in the over-65s, combined with another healthcare intervention and using the KMD, was cost-effective and financially beneficial, compared with no screening at all. Fourthly, the participants felt that screening for AF was important, that they were happy for clinical pharmacists to perform the screening, and they were very impressed by the noninvasive digital technology that was used and the information they received from the clinical pharmacist during the appointment. Finally, and arguably the most notable finding, using pulse palpation alone resulted in a larger number of false-positive AF diagnoses compared with the KMD (7.8% vs 2.6%).

Strengths and limitations of the study {#sec029}
--------------------------------------

A key strength of this study was that screening was performed during the influenza vaccination season. Since the risk factors associated with AF overlap with those patients invited to participate in the seasonal influenza vaccination \[[@pmed.1003197.ref045]\], combining these health interventions allowed us to optimise recruitment of a relevant and at-risk population of participants with an interest in their own personal well-being and generally in good health at the time of screening. In addition, basing the screening within GP practices and combining it with another healthcare intervention was cost-effective and convenient for patients and ensured that patients received and had access to the necessary follow-on care (e.g., ~12L~ECG and treatment) and support for an AF or other cardiovascular diagnosis. This is often missing from studies performed in other primary care settings, such as community pharmacies. However, the space requirement, logistics, and staff endorsement of such a screening strategy in some GP practices may be prohibitive. A single-time-point strategy can also mean that those with PAF are less likely to be detected compared with those with persistent and permanent AF.

Using an ~SL~ECG device such as the KMD, which provides a recorded 'snapshot' of a person's heart rhythm, not only was beneficial to patients with possible AF but may also help patients that have other previously undetected cardiovascular complications requiring new treatment or treatment adjustment, for instance, heart failure or sinus bradycardia. However, many of these non-AF cardiovascular diagnoses appeared as an 'unclassified' result and required manual assessment of the ECG by a cardiac specialist and/or confirmation by a ~12L~ECG.

A key limitation, although perhaps inevitable of any screening setting, was that the intervention did not reach those patients who either by choice or circumstance were unable to attend the practice for an influenza vaccination. These included the housebound, those with transport issues, patients based in residential and nursing homes, or those that simply do not engage with healthcare interventions such as the influenza vaccination \[[@pmed.1003197.ref046]--[@pmed.1003197.ref048]\]. It is likely that many of these patients, who have limited access to healthcare, are perhaps in most need of such screening interventions. Indeed, in studies involving care-home residents, based in the United States and Norway, the AF prevalence was found to range from 6.9% to 18.8% \[[@pmed.1003197.ref049],[@pmed.1003197.ref050]\], which at the peak is eight times higher than the prevalence of AF in the general population \[[@pmed.1003197.ref051]\].

Another limitation of the study was the underrepresentation of UK ethnic minority groups. This study involved predominantly White British participants (97%) and was thus not a true representation of the average UK population, which is 80.5% White British \[[@pmed.1003197.ref052]\] (93.7% in Kent \[[@pmed.1003197.ref053]\]). Expanding this study into areas where there is a higher representation of ethnic minority groups would be required to make it nationally representative.

Measuring the accuracy of the pharmacist to detect AF using the ~SL~ECG was limited by the protocol design, in which the automated algorithm was retained on the KMD. The interpretation of the ~SL~ECG by the algorithm may have influenced the diagnostic decision made by the pharmacist, potentially increasing the risk of misclassification bias, and thus the level of diagnostic accuracy observed may not be truly representative of their capability. Similarly, the accuracy of the pharmacist to pulse palpate may have been compromised by their relatively limited training and experience; however, this is perhaps representative of the majority of HCPs and certainly the general population for which pulse palpation is being actively promoted.

Comparison with other studies {#sec030}
-----------------------------

The detection of 'new' AF in this study was low (0.7%) but comparable to some of the other studies screening asymptomatic patients ≥65 y old using the KMD where it varied from 0.5% to 1.7% \[[@pmed.1003197.ref018],[@pmed.1003197.ref054],[@pmed.1003197.ref055]\]. This low detection rate may be due in part to the high prevalence (3.6%) of 'known' AF already in this screened population. The overall prevalence of AF 'known' and 'new' in this study was 4.3%, which was consistent with findings from previous studies based in GP and outpatient settings (4.4% \[95% CI 4.1--4.6%\]), as reviewed by Lowres and colleagues (2013) \[[@pmed.1003197.ref051]\]. Interestingly, enhanced demographics collected from the medical records of 100 random participants that had been determined as having normal SR by the cardiologist showed that 7% of these 100 participants had experienced (or were experiencing) known AF/PAF, although all were in normal SR at time of screening. This suggests that the true prevalence of AF in this population is actually higher than is stated and could potentially be as high as 12.3%, as was found in the STROKESTOP study \[[@pmed.1003197.ref056]\].

Our study showed that those participants with AF were more likely to be older males with a higher BMI and a CHA~2~DS~2~-VASc score not lower than 3.0. These data are consistent with previous studies \[[@pmed.1003197.ref011],[@pmed.1003197.ref012],[@pmed.1003197.ref014]\]. Our data also highlighted that none of the AF cohort had 'lone' or idiopathic AF, but all had one or more conventional risk factors for AF, of which hypertension, renal disease, and diabetes mellitus were the most common \[[@pmed.1003197.ref011],[@pmed.1003197.ref013],[@pmed.1003197.ref014]\]. These findings are consistent with the literature, which has shown 'lone' AF to affect as little as 3% of the AF population and to occur mainly in those with PAF who are under the age of 60 \[[@pmed.1003197.ref057]\], whereas the presence of co- or multimorbidities is much more common in those with AF and reported in a number of studies \[[@pmed.1003197.ref012],[@pmed.1003197.ref014],[@pmed.1003197.ref054]\] and is associated with an increased lifetime risk of developing AF \[[@pmed.1003197.ref011]\]. Targeted AF screening of the older population experiencing one or more risk factors that overlap with the medical indications recommended for the influenza vaccination \[[@pmed.1003197.ref045]\] would likely make this a viable screening strategy.

Importantly, this study directly compared the accuracy of pulse palpation by the clinical pharmacist with the use of digital technology (KMD). Few studies have directly compared pulse palpation with the newly available digital technology for the detection of AF, despite pulse palpation being the recommended method for first-line detection of AF by NICE and charities such as the Arrhythmia Alliance \[[@pmed.1003197.ref031],[@pmed.1003197.ref058]\]. Three studies reported that pulse palpation had much lower specificity than the newer technology \[[@pmed.1003197.ref059]--[@pmed.1003197.ref061]\]. Indirect comparisons reported in systematic reviews demonstrated that pulse palpation in six studies showed reasonable sensitivity (0.92 \[0.85--0.96\]) as a technique; however, specificity (0.82 \[0.76--0.88\]) was much lower compared with other methods \[[@pmed.1003197.ref029]\]. In this study, sensitivity and specificity of pulse palpation by the clinical pharmacist was much lower than using the KMD. The KMD had superior specificity in the detection of AF, with over 5%, fewer false-positive results, than pulse palpation. The operating capabilities of the KMD and its algorithm in this study were also found to be comparable to previous studies in similar or different settings, where sensitivity and specificity varied between 55% and 100% and 82% and 99%, respectively \[[@pmed.1003197.ref042],[@pmed.1003197.ref062]--[@pmed.1003197.ref065]\].

Reliance on pulse palpation alone would have resulted in a higher number of false positives and false negatives. Interestingly, few studies quote the percentage of false discoveries, i.e., the number of AF diagnoses from all the potential AF diagnoses that were incorrect. This is perhaps because these numbers appear to be alarmingly high. In this study, pulse palpation had an FDR of 69%. In other words, using pulse palpation in isolation would have resulted in 65 out of 604 participants being informed that they potentially had AF, but 45 of these would have been incorrect. The KMD had an FDR of 38.5% (15 out of 39). This is not a negligible amount, but considerably better than for pulse palpation. The issue of using pulse palpation as a first step in the detection of AF is that an irregular pulse is an indicator not just of AF but also of many other conditions \[[@pmed.1003197.ref029]\], and therefore, 70%--87% of all pulse irregularities will not be AF \[[@pmed.1003197.ref066]\]. Consequently, mass screening using pulse palpation will lead to a high number of false positives and, to a lesser extent, false negatives when used solely as a screening test for AF \[[@pmed.1003197.ref029],[@pmed.1003197.ref059],[@pmed.1003197.ref060]\]. For many patients, being told that they possibly had AF would likely cause undue worry and concern if not dealt with correctly by those doing the screening and would be particularly problematic if the patient was independently screening themselves.

This study also demonstrated that screening for AF in primary care during the influenza vaccination season, using a KMD device and clinical pharmacist, was likely to be cost-effective in nearly 72% of cases at a threshold of £20,000 per QALY, compared with no screening at all. These health economic outcomes are aligned with health economic evaluations in other studies using similar conditions \[[@pmed.1003197.ref042],[@pmed.1003197.ref043],[@pmed.1003197.ref067]\].

Interestingly, AF screening results presented here revealed that only seven out 18 patients with previously diagnosed AF were fully aware of their condition. In line with these findings, less than 50% of respondents to questionnaires were aware of AF and related health risks prior to being screened. Although the phenomenon of poor AF awareness amongst the general public is not new \[[@pmed.1003197.ref068]\], it highlights the value of healthcare education provided by qualified HCPs, such as pharmacists, undertaking the screening. In turn, respondents to the questionnaire appreciated the informative and user-friendly consultation with the pharmacist, which improved their access to healthcare and provided immediate reassurance. As reported by previous AF screening studies in primary care \[[@pmed.1003197.ref017],[@pmed.1003197.ref069],[@pmed.1003197.ref070]\], patients were also fascinated by ~SL~ECG technology, showcasing the potential of using KMD as a multipurpose screening and educational tool by future AF screening initiatives.

Conclusion and policy implications {#sec031}
----------------------------------

Future screening initiatives will require the involvement of HCPs based in general practices, in particular, clinical pharmacists. Clinical pharmacists can mitigate stress that may occur due to false discoveries; have the potential to treat and manage both the condition and the associated risk factors linked to other coexisting diseases; and can educate the population about the disease. Their participation can assure the longevity of any future AF screening programmes. This study highlights the need for a change in guidelines to move from less reliable and less sensitive practices such as pulse palpation as the first line of AF detection to the adoption of specifically purposed modern technology.

Future direction {#sec032}
----------------

The present study has demonstrated that coupling an AF screening initiative with the influenza vaccination programme is feasible and cost-effective and has a high degree of acceptability to patients. However, key questions remain relating to whether this model could be upscaled and delivered by pharmacists or other HCPs, in all GP practices, and without the \'insurance\' of a cardiologist screening all ECGs. Acceptability by patients has been reported here; however, the key barriers perceived by policymakers that have prevented the adoption of a national programme are yet to be explored. Furthermore, the service is not equitable, because although it was freely available to all, those who are more proactive about their health are more likely to participate. Further research, therefore, needs to focus on more inclusive strategies to ensure that routine AF screening is available to those from differing social, economic, and cultural backgrounds.

Supporting information {#sec033}
======================
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(PDF)
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###### Demographic comparison of random normal and possible-AF participants.
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7\. Please reiterate a brief description of the content analysis approach cited on line 201.

8\. In your STARD checklist, please use section and paragraph numbers, rather than page numbers.

9\. PLOS Medicine requires that the de-identified data underlying the specific results in a published article be made available, without restrictions on access, in a public repository or as Supporting Information at the time of article publication, provided it is legal and ethical to do so. Please see the policy at <http://journals.plos.org/plosmedicine/s/data-availability> and FAQs at <http://journals.plos.org/plosmedicine/s/data-availability>\#loc-faqs-for-data-policy

10\. Please provide a copy of the questionnaire used in your study as a Supporting Information file.

11\. The usefulness of the word cloud is limited, so we would advise not including it in your manuscript.

Comments from the reviewers:

Reviewer \#1: This is a manuscript on screening for atrial fibrillation performed by clinical pharmacists during influenza vaccination season in a general practice setting. Individuals attending influenza vaccination aged above 65 were offered examination using pulse palpation and one-lead ECG (Kardia Mobile). Pharmacists were trained in palpating pulse and in recording and interpreting one-lead ECG. Results from pharmacist examinations were compared to ECG interpretation by cardiologist. The manuscript also includes a health economy assessment and results from feedback given by the participants. The authors concluded that the screening procedure was feasible, economically viable and positively endorsed by participants.

Comments:

1\. In general, I believe that the manuscript is too voluminous, and the present volume will probably discourage some readers from reading the entirety. I suggest putting the health economy data in a separate paper.

2\. The title: If you offer a screening measure to an individual who is attending health care for another reason, the screening is opportunistic, not systematic. The title also implies that this is population screening, but since not all aged above 65 will get the screening invitation, I am reluctant to describe this screening effort as population-based.

3\. Abstract: even though feasibility is the primary outcome, many readers would like to find data on the screening yield as well in the abstract.

4\. I would designate the Kardia ECG device digital technology but hardly novel.

5\. It is reported that 604 patients were screened, but how many were offered screening in total and how many declined? This is core data when judging a screening program. Furthermore, if there were data on the number of inhabitants aged over 65 in the catchment areas one could estimate the proportion of the population reached by this screening effort. As a suggestion, the boxes in figure 1 should contain numbers reporting the loss of participants at different stages.

6\. Introduction, line 56: Hypertension and heart failure are more common co-morbidities in AF.

7\. Clinical pharmacists and cardiologists were not blinded from knowing the ECG interpretation made by the Kardia Mobile algorithm. This could have affected their ECG interpretation and is a major limitation of the validation part of the study and should be recognised as such.

8\. Why was not medical history collected from all participants?

9\. This study was intended to validate the use of clinical pharmacists in AF screening and their ECG interpretation as compared to ECG interpretation made by a cardiologist. Since the absolute precision is depending on prevalence of atrial fibrillation, which was low in the screened population, one must consider sample size, i.e. what is the absolute precision in the validation trial with the reported sample size and AF prevalence?

10\. Table 1: A percent sign after percentages would increase readability. Abbreviations m and bpm should be explained.

11\. It is reported that only 1% of single lead ECG recordings were deemed as uninterpretable by a cardiologist. This is a very low proportion as compared to previous studies. Were there in some cases multiple recordings performed to achieve acceptable signal quality?

12\. Paragraph \"SLECG interpretation by the clinical pharmacists\" starting on line 307: Many of the results in the text are duplicated from table 2, this should be avoided. The Cohens kappa coefficient should be added to table 2.

13\. Paragraph \"AF prevalence\" starting on line 342: I have difficulties following the figures reported here. It is stated that 18/26 patients had known AF, which implies that the remaining 8 were identified from screening. It is stated on line 345 that 4/604 new cases were diagnosed within the screening project. The figures in the upper part of this paragraph should be revised and clarified. How many participants were diagnosed with new AF?

14\. In the same paragraph, it is stated on line 349 that all 26 \"actionable\" AF participants were eligible for OAC treatment and that 20/26 were on this treatment at the end of the study. How many of these 20 treated patients had known AF and newly diagnosed AF? How many of the patients with known AF (n=18) had OAC treatment on study entry? This figure is vital for the health economy assessment.

15\. Line 368: the statistical methods used should only be reported in the methods section.

16\. Table 5: Many of the ECG conditions described in table 5 (BBB, low-grade AV-block) will not lead to additional investigations in asymptomatic patients. The therapeutic implication is very different in low-grade and in high-grade AV-block, these should be classified. Were any participants referred for pacemaker implantation?

17\. Discussion, line 473: there are no data provided supporting the statement that patients with \"possible cardiovascular complications\", i.e ECG deviations, have a benefit from the screening procedure.

18\. Discussion, line 507: Given the median age of 73 years of the studied population, I don´t find an AF prevalence of 3.6% high, it is surprisingly low. In the Swedish STROKESTOP 1 trial (Svennberg et al, Circulation 2015:131;2176-84), the baseline prevalence of AF was 9.3% among participants in a population aged 75 and 75.

19\. Discussion, line 525: I don´t think that there is enough data presented to appoint this protocol to the \"optimal screening strategy\", I suggest removal of this sentence.

20\. Conclusion: this paragraph is far too long. I suggest shortening it to 5-10 lines.

Reviewer \#2: Thank you for the opportunity to read and review your manuscript \"Systematic population screening for atrial fibrillation by clinical pharmacists in general practice during the influenza vaccination season: the PDAF study\". The manuscript is of interest particularly to readers engaged in AF screening, as well as those interested in the involvement of pharmacists in public health initiatives and medical practice.

GENERAL COMMENT

The text is somehow repetitive and written in a verbose style. Much of this could be improved by rephrasing and possibly move some parts to an additional Supplementary document. I.e. details about the participants experience questionnaire; details about how the screening was perceived, which are mentioned in Results and repeated in the Discussion. Furthermore, much results are presented in detail both in the text and in Tables, which may be unnecessary for all numbers.

MAJOR COMMENTS

The manuscript seems long, as it is perceived by this reviewer. A full word count is not available as far as I can see, and can not be retrieved from the available PDF. I trust the Editors may comment on the length of the manuscript with regard to the requirements of the journal, but also for the readability, I would strongly suggest shortening. For example, the Introduction may benefit from shortening, such as the section from page 3, line 64 to page 5, line 92, largely desribes (and discusses) challenges within the UK primary care system. This could be shortened to a few sentences with regard to the focus of this manuscript.

I think parts of the Methods description, which are very well described in detail, is presented almost like a protocol, and parts of this could, for the benefit of the reader, be moved to a Supplementary document. For example; page 8, line 160-167 (participants experience questionnaire) could be shortened. Instead of details about the questionnaire, 1-2 sentences could remain in the manuscript, and even more could be included in a Supplementary (even consider writing out in full the questions asked).

The first parts of the Results section are clearly presented. However, you may consider shorten down some of the results repeatedly presented both in the text and in Tables; for example all values for sensitivity, specificity etc. also presented in Table 2.

Furthermore, I would question the relevance of the reported heart rate results (page 15, line 323-327). Although a small but significant difference was found, is this clinical relevant? The manual pulse palpation was followed by the KMD, i.e. not performed simultanously, and this could easily explain the observed difference.

I would question the validity/relevance of the reported sl-ECG interpretation by the clinical pharmacists, who have (if I understand correctly) just recorded the KMD algorithm interpretation (SR, AF etc.) before recording their own interpretation, which must potentially be biased by the algorithm, reflected in very comparable numbers. Were the 39 cases of \"possible AF\" (as interpreted by the KMD) the exact same participants as the 39 cases recorded as \"possible AF\" by the pharmacists? Or did the pharmacists question the automatic algorithm? I can see that this is again further discussed in the Discussion section (page 24, line 494-501). I would suggest to omit these results, or report this as registered \"per protocol\", but reduce the importance of this. You may also consider rephrasing this in the Discussion. I would assume the pharmacists must have been biased by the KMD (and not as stated now, page 24, line 496-497; that the KMD \"\...may have influenced the diagnostic decision made by the pharmacist\...\".

This reviewer is not capable of fully assessing the cost-effectiveness evaluation of the screening. However, I would humbly state that I find cost-effectiveness assessments without endpoints (stroke and mortality) troublesome. This is a general comment relevant also for other previous publications regarding AF screening. Although extensive cost-effectiveness analyses have been performed, the costs included/saved in the analysis rely on the basic assumption that screen-detected AF has the same clinical course and risk of stroke, as \"ordinary\" clinically detected AF. Although this is a likely assumption to make, it is yet to be proven. Furthermore, some numbers in the assumptions made for the \"base case\", such as a KMD-identified new possible AF rate of 1,3%, is not clear to me. The prevalence of screen-detected AF is 0,7%, and I do not find this number in the analysis. However, this may be right. I am also not fully able to assess how the analysis has taken all other findings (non-AF findings) into account; these may, in a real-life setting, produce a substantial cost for the healthcare system, not to mention unnecessary anxiety and repeated examinations. But, my apologies as I do not have the necessary knowledge to fully assess these analyses.

MINOR COMMENTS

Page 3, line 46: Reference \#2 does not seem to be the most representative publication to document a growing prevalence of AF. Examples of relevant references could be Ball et al (Int J Cardiol, 2013) or Willams et al (Am J Cardiol, 2017).

Page 3, line 48-50: Reference \#7 is an industry-initiated \"white paper\". Although it seems balanced and well written, I would suggest you rather use a comparable relevant and independent publication, such as the white paper \"Screening for Atrial Fibrillation\" by Freedman et al (Circulation, 2016), also providing a strong case to improve early detection and screening for AF.

Page 28, line 577: Language-wise: \"year by year\" instead of \"year on year\"?

Reviewer \#3:

This manuscript evaluated an intervention to perform screenings for atrial fibrillation (AF) during visits to a pharmacist for a routine influenza vaccination. The paper assessed both the accuracy of pharmacists assessments using SL-ECG kardia mobile device and the cost effectiveness of a related screening strategy using a simulation informed by the study. Overall, finding new ways to provide screening for common, but serious, health conditions like AF during provision of routine services is a worthwhile goal. However, I have several concerns about the manuscript.

General comments

1\. The two main parts of the study (i.e., the assessment of the accuracy of the screening test and the cost effectiveness study) seem very disconnected. As written, I cannot be certain whether this is simply a disconnect in the way the studies are described or in content.

2\. The cost effectiveness analysis was difficult to follow and lacked key details (some specific instances are pointed out in the specific comments below). If this component of the study is to be included, it needs to be fleshed out so that the purpose (e.g., what is being compared) as well as the base and alternative scenarios are clear.

3\. The methods section seemed to omit key details related to the assessment of accuracy of the proposed screening approach. Specific instances are referenced in the specific comments below.

4\. Restructuring the introduction to highlight the purpose of both components of the study (i.e., the accuracy assessment and the cost effectiveness study) would strengthen the manuscript.

Specific comments

1\. Page 5, line 96: should this line read, \"we evaluated the use of a single-lead electrocardiogram device \*compared with\* pulse palpation alone...\"?

2\. Page 5, line 103: is there a similar checklist or list of standard for reporting results from cost effectiveness studies?

3\. Page 6, line 121: were pharmacists aware who had pre-existing AF?

4\. Page 6, line 124: \"consecutive sampling\" should be described in more detail. Were all patients who were eligible offered screening?

5\. Page 6, last paragraph: it seems like there is a sentence or 2 missing here to describe the pharmacists reading of the SL-ECG?

6\. Page 8, line 172: what is a \"non-parametric\" variable?

7\. Page 8, line 177: When missing data were omitted from the analysis, how was this done? Were participants with any missing data excluded from the entire study or simply excluded from specific analyses where that data point was required?

8\. Page 8, last paragraph: I recommend defining the diagnostic accuracy parameters here (e.g., sensitivity, specificity, positive predictive value, and false discovery rate) here. In addition, the term \"accuracy\" comes up in the results and is not defined here.

9\. Page 9, line 193: This paragraph was difficult to follow. The first sentence appears to define \"diagnoses of AF\", but the definition appears to be for AF prevalence. In addition, this paragraph is the first reference (that I see, apologies if I have missed it) to the 12-lead ECG. What is this and what is its purpose in the study?

10\. Page 9, line 201: Here, the manuscript should note the purpose behind analyzing the questionnaire using a content-analysis approach.

11\. Page 10, line 210: where does the 1.3% come from in this line? I thought the prevalence of newly identified AF in the study was 0.7%?

12\. Page 10, line 217: The description of the hypothetical screening program needs more detail. Moreover, this sentence makes it unclear if the hypothetical population studied included all those who underwent screening or only those who screened positive and were offered oral anticoagulation medications.

13\. Page 10, line 220: What was the purpose of the 3-month cycles? Were these timepoints when outcomes were assessed? This should be clarified.

14\. Page 10, line 229: This section of the paper should clearly describe the base cases and alternative scenarios. For example, costs were varied between 50% and 150% of base case, but unclear what these costs are for.

15\. Page 11, first paragraph: incremental cost effectiveness ratios should be defined here at first use.

16\. Table 1: the variables described in this table should be defined in the Methods section, particularly defining how \"alcohol drinker\" and \"positive smoking status\" were defined. For example, does this include ever using alcohol or current use only?

17\. Page 15, line 326: is the difference in measured heart rate simply \"statistically significant\" or is this difference also clinically meaningful? Offering some guidance to readers, here or in the discussion, would be helpful.

18\. Page 16, line 351: from this line and the section on follow-up data and outcomes, it appears that there may be a section missing from the methods where follow-up actions should be described.

19\. Page 18, line 382: what was the threshold used to defined \"cost effective\" in this study?

20\. Page 18, line 384: It is unclear to me how \"participants\" were defined here. Was this a cost for all screened individuals, everyone in the population, or some other group?

21\. Discussion: some discussion of variability in results between pharmacists would be helpful. Moreover, the discussion would be strengthened by addressing implementation science questions, such as the time required to train pharmacists on the methods needed and whether one would expect accuracy to decline as the intervention was scaled up.

22\. Page 27, line 551: should this be \"... better than for pulse palpation.\"?

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003197.r003

Author response to Decision Letter 1

8 May 2020

###### 

Submitted filename: Response to reviewers.pdf

###### 

Click here for additional data file.

10.1371/journal.pmed.1003197.r004
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28 May 2020

Dear Dr. Veale,

Thank you very much for re-submitting your manuscript \"Opportunistic screening for atrial fibrillation by clinical pharmacists in general practice during the influenza vaccination season: a cross-sectional feasibility study.\" (PMEDICINE-D-20-00198R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by three reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jun 04 2020 11:59PM.

Sincerely,

Artur Arikainen,

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

1\. Please implement the reviewers' final comments. However, please note that you can leave in references in the Discussion section, as long as they are relevant in framing your findings in the context of existing literature.

2\. Please amend the Title slightly as follows to mention the locale of the study: "Opportunistic screening for atrial fibrillation by clinical pharmacists in UK general practice during the influenza vaccination season: a cross-sectional feasibility study" (no full stop at the end).

3\. Lines 16-17: Please update to: "Growing prevalence of atrial fibrillation (AF) in the ageing population, and its associated life-changing health and resource implications, have led to a need to improve its early detection."

4\. Line 31: Please define "CHA2DS2-VASc".

5\. In your abstract and throughout the paper, please quote p values alongside 95% CI, where available. Lines 31-32: We suggest removing the p values. We generally ask that exact p values are quoted, except where p\<0.001, but do not favour quoting them in isolation.

6\. Line 39, please replace \"overwhelmingly\" with \"generally\", or similar.

7\. Please adapt the sentence summarizing study limitations (lines 39-40) to quote one additional limitation, e.g., the limited ethnic representation in the study cohort.

8\. Please remove the apostrophe from \"its\" at line 49.

9\. Please adapt reference call-outs to the following style: \"\... health implications \[4,5\], combined \...\" (no space after commas in square brackets).

10\. Line 100: Please give exact date ranges.

11\. Please remove trademark symbols, e.g. at line 109.

12\. Please substitute \"sex\" for \"gender\" where appropriate, e.g. at line 128.

13\. Lines 234 and 236: Please clarify in the text whether the figures in square brackets show range or another statistic.

14\. Table 3: Please give exact p values for all comparisons, including those that are not significant.

15\. Table 4: Please replace this with a flowchart, as also recommended by a reviewer. Please also list the abbreviations alphabetically, and include a definition for PR.

16\. Lines 387-393: Please provide quantitative data (eg. proportions of patients) to support these statements.

17\. Line 397: Please remove the subjective descriptor "comprehensive".

18\. Line 540: Please avoid stating "effective", as also recommended by a reviewer.

19\. Please correct the link for references 1 and 44.

20\. Author Summary:

a\. Please include the Author Summary in your main manuscript file -- after the Abstract, before the Introduction.

b\. Bullet point 2: Replace "morbidities" with "conditions" (for clarity to a non-scientific reader).

c\. Bullet point 3: Define GP.

\-\-\-\-\-\--

Comments from Reviewers:

Reviewer \#1: The authors have addressed the majority of my comments on the initial version.

I still have a few comments to the revision now presented:

1\. The manuscript is still very extensive and not just in terms of word count. There are data on AF prevalence and screening yield, comparison between diagnostic modalities, qualitative data and finally data on cost effectiveness.

2\. I still find it difficult to follow all the figures presented in \"AF prevalence\". A flowchart would be of great help.

3\. The ECG findings and diagnosis presented in table 4 are mostly benign findings that will not have any relevance for asymptomatic patients, i.e ectopics and most conduction abnormalities. I suggest toning down this part of the findings.

4\. In \"Future direction\", it is stated that \"The present study has demonstrated that coupling an AF screening initiative with the influenza vaccination programme is effective.\" The effectiveness of a screening program is defined as its ability to reduce the morbidity and mortality associated to the screened condition, this is not demonstrated with this study and I suggest rephrasing.

5\. Conclusion is still too long should preferably not contain references, rather conclusions based on data from the present study.

6\. The low performance of pulse palpation as a screening tool should be emphasized, and the superiority of the digital device over pulse palpation is one of the major results.

7\. The suitability of a GP office as a screening central for AF to my opinion a theoretical construct. As partly mentioned in the introduction, the current staffing and workload in primary care is not compatible with additional tasks like AF screening, at least not beyond what is made by the tremendously committed investigators in local screening initiatives like in this one. There still very little evidence that AF screening could be done in the primary care setting apart from delimited clinical trials, and to what extent can this study change that?

Reviewer \#2: The Authors have provided a satisfactory response and the manuscript has been revised accordingly. I would recommend that the manuscript is accepted for publication.

Reviewer \#3: This revision is very responsive to my previous comments. Only a few thoughts remain:

1\. Follow-up from previous review: I recommend replacing \"non-parametric\" variable with \"continuous variable\". The variable itself cannot be parametric (parametric assumptions are imposed by the analyst).

2\. I still think the paper could be strengthened by discussion of implementation science type questions. While I agree with the authors that additional analyses are unnecessary, the discussion would be strengthened by considering points like \"is the time required to train pharmacists on the methods needed worth the improvements noted\" and whether the authors expect accuracy to decline as the intervention was scaled up (and moreover, what could be done to prevent this). These questions are important if the work is expected to inform future adoptions of this intervention in other settings. It might be that the authors believe that this approach can be scaled up without loss of accuracy due to important features of the tool, which would be important to note.

3\. Based on the methods section, I expected Table 2 to compare sensitivity, specificity, positive predictive value, and false discovery rate. However, it is unclear what measure \"accuracy\" in Table 2 refers to? This should be clarified with a footnote or renamed.

4\. Page 9, line 192: the definitions for PPV and FDR should be clarified. PPV should be (\# who both tested positive and were true positives) / (\# who tested positive). Similarly the FDR should be (\# who both tested positive and were true negatives)/(\# who tested positive). Given that the FDR is simply 1-PPV, it may be more informative to report the PPV and the NPV (negative predictive value = (\# true negatives who tested negative)/(\# who tested negative). But I leave it up to the authors to determine the most useful metrics.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003197.r005

Author response to Decision Letter 2

7 Jun 2020
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16 Jun 2020

Dear Dr Veale,

On behalf of my colleagues and the academic editor, Dr. Trygve Berge, I am delighted to inform you that your manuscript entitled \"Opportunistic screening for atrial fibrillation by clinical pharmacists in UK general practice during the influenza vaccination season: a cross-sectional feasibility study\" (PMEDICINE-D-20-00198R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Artur Arikainen,

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: The authors have declared that no competing interests exist.
